In this report, we describe the molecular pharmacology of a novel, highly potent and specific URAT1 inhibitor, verinurad (also known as RDEA3170; Figure S1), that is currently under evaluation for the treatment of gout and asymptomatic hyperuricemia. This evidence concerns the gene SLC22A12 and gout.